Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORA | P35398 | 1/20 | 0.43 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | RHOA | P61586 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ANXA2 | P07355 | 1/20 | 0.40 |
| ▸ | S100A10 | P60903 | 1/20 | 0.40 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17491450 | 0.82 | IMPDH2 (0.46) | NR2E1ROCK2IMPDH2AAK1EGFR | |
| SCHEMBL17491488 | 0.82 | EGFR (0.42) | IMPDH2AAK1RHOAEGFRFGFR1 | |
| SCHEMBL17491494 | 0.80 | ALDH1A1 (0.46) | IMPDH2AAK1RHOAEGFRFGFR1 | |
| SCHEMBL17491527 | 0.80 | LMNA (0.46) | IMPDH2AAK1RHOAEGFRFGFR1 | |
| SCHEMBL17491394 | 0.79 | ALDH1A1 (0.49) | IMPDH2AAK1RHOAEGFRFGFR1 | |
| SCHEMBL17491395 | 0.79 | SMN1; SMN2 (0.52) | ROCK2IMPDH2AAK1RHOAEGFR | |
| SCHEMBL17506981 | 0.79 | AAK1 (0.52) | IMPDH2AAK1RHOAEGFRFGFR1 | |
| SCHEMBL17491452 | 0.79 | RHOA (0.39) | RORANR2E1ROCK2IMPDH2AAK1 | |
| SCHEMBL17491415 | 0.78 | BRAF (0.47) | NR2E1IMPDH2RHOAEGFRFGFR1 | |
| SCHEMBL17491420 | 0.78 | NPC1 (0.65) | NR2E1IMPDH2RHOAALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2982670-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-11-07 | — | — | EP | disclosed |
| US-9624184-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-18 | — | — | US | disclosed |
| US-9624184-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-18 | — | — | US | disclosed |
| US-9624184-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-18 | — | — | US | disclosed |
| US-20160052897-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-25 | — | — | US | disclosed |
| EP-2982670-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-02-10 | — | — | EP | disclosed |
| EP-2982670-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052897-A1 | HETEROCYCLIC COMPOUND | PSEN1, PSEN2, BACE1 | RORA 504/4885NR2E1 977/4885MGLL 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.